Pharmaceutical group · Ireland
JAZZ
A group of 11 companies with 33 medicines in 5 countries.
Group structure
11 companies in 4 countries
Loading…
Pharmaceutical group · Ireland
A group of 11 companies with 33 medicines in 5 countries.
11 companies in 4 countries
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine of every company in the group, current ones first.
1–25 of 33
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| DEFITELIO80 mg / ml · Solution | Defibrotide | Canada | Marketed | 2017 |
| DEFITELIO200mg/2.5ml (80mg/ml) · Solution | Defibrotide | United States | Marketed | 2016 |
| Enrylaze | Asparaginase | EU (EMA) | Authorised | 2023 |
| Enrylaze 10 mg/0,5 ml oplossing voor injectie/infusieOplossing voor injectie of infusie | Asparaginase | Netherlands | Authorised | 2023 |
| ENRYLAZE 10 MG/0,5 ML, SOLUCION INYECTABLE Y PARA PERFUSION10 mg · Solución inyectable y para perfusión | Asparaginase | Spain | Marketed | 2024 |
| EPIDIOLEX100 mg / ml · Solution | Cannabidiol | Canada | Marketed | 2024 |
| EPIDIOLEX100mg/ml · Solution | Cannabidiol | United States | Marketed | 2018 |
| Epidyolex | Cannabidiol | EU (EMA) | Authorised | 2019 |
| Epidyolex 100 mg/ml, drankDrank | Cannabidiol | Netherlands | Authorised | 2019 |
| EPIDYOLEX 100 MG/ML SOLUCION ORAL100 mg/ml · Solución oral | Cannabidiol | Spain | Marketed | 2019 |
| FAZACLO ODT100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 150MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 200MG **Federal Regis · Tablet, orally disintegrating | Clozapine | United States | Not marketed | 2004 |
| LUVOX CR100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 150MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Capsule, extended release | Fluvoxamine | United States | Not marketed | 2008 |
| RYLAZE10 mg / 0.5 ml · Solution | Asparaginase | Canada | Marketed | 2023 |
| RYLAZE10mg/0.5ml · Injectable | Asparaginase erwinia chrysanthemi -rywn | United States | Marketed | 2021 |
| VYXEOS100mg; 44mg · Powder | Cytarabine, Daunorubicin | United States | Marketed | 2017 |
| VYXEOS100 mg + 44 mg · Powder | Cytarabine, Daunorubicin | Canada | Marketed | 2021 |
| Vyxeos liposomal 44 mg/100 mg poeder voor concentraat voor oplossing voor infusiePoeder voor concentraat voor oplossing voor infusie | Cytarabine, Daunorubicin | Netherlands | Authorised | 2018 |
| VYXEOS LIPOSOMAL 44 MG/100 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION44 mg + 100 mg · Polvo para concentrado para solución para perfusión | Daunorubicin, Cytarabine | Spain | Marketed | 2018 |
| Vyxeos liposomal (previously Vyxeos) | Daunorubicin, Cytarabine | EU (EMA) | Authorised | 2018 |
| XYREM500 mg / ml · Solution | Sodium oxybate | Canada | Marketed | 2007 |
| XYREM0.5gm/ml · Solution | Sodium oxybate | United States | Marketed | 2002 |
| XYWAV0.234gm/ml; 0.096gm/ml; 0.13gm/ml; 0.04gm/ml · Solution | Sodium oxybate | United States | Marketed | 2020 |
| XYWAV0.234 g / ml + 0.096 g / ml + 0.13 g / ml + 0.04 g / ml · Solution | Sodium oxybate | Canada | Marketed | 2023 |
| ZEPZELCA4 mg / vial · Powder | Lurbinectedin | Canada | Not marketed | 2021 |
| ZEPZELCA4mg/vial · Powder | Lurbinectedin | United States | Marketed | 2020 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 11 | 10 | 1 | CompaniesAll medicines |
| Canada | 10 | 8 | 2 | CompaniesAll medicines |
| Spain | 4 | 4 | 0 | CompaniesAll medicines |
| European Union (EMA) | 4 | 4 | 0 | CompaniesAll medicines |
| Netherlands | 4 | 4 | 0 | CompaniesAll medicines |
Also in the registers of Colombia, France, Italy, Sweden, United Kingdom
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia, CUM vigentes; source update 2026-09-16; acquired 2026-10-08.
Licence: CC BY-SA 4.0
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
BDPM / ANSM, HAS and UNCAM, CIS_MITM.txt, published 13/10/2026, acquired 2026-10-25T22:15:46.803459+00:00; exact facts retained, no endorsement.
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; October 2026 register, published 7 October 2026; https://assets.publishing.service.gov.uk/media/6ac660fdec9d3aba1e0139d9/MS_Register_-_October_2026.csv; acquired 2026-10-13T22:59:02.704630+00:00; CSV-to-role/site projection is an adaptation under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; Crown copyright MHRA factual register
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; https://www.gov.uk/government/publications/marketing-authorisations-granted-in-2026; publication updated 7 October 2026; source PDF periods January–September 2026; original bytes acquired 18 October 2026; PDF page/table/exact-authorisation projections by Prognia under OGL v3.0.
Licence: Open Government Licence v3.0; GOV.UK Crown copyright publication and linked factual MHRA grant registers
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_A_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:41 GMT; acquired 2026-10-13T17:21:06.055244+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Läkemedelsverket, Sweden, Förvaringstemperatur och hållbarhet, source extract 2026-10-20, acquired 2026-10-20T20:46:08.868635+00:00. Original cells retained; structured adaptation by Prognia. No regulator endorsement.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
Läkemedelsverket, Sweden, Läkemedelsprodukter, source extract 2026-10-20, acquired 2026-10-20T20:45:53.483733+00:00. Original cells retained; structured adaptation by Prognia. No regulator endorsement.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Keep JAZZ’s medicines accurate on Prognia, see how professionals use them and answer what they ask. A 20-minute call, in English.
Book a callWell-known pharmaceutical groups, each with all its companies.